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Abstract
Butamidine analogues possessing unsaturation in the ether bridge between the bisamidinophenyl
or bisimidazolinophenyl functionalities have been synthesized as semirigid congeners of
pentamidine. These compounds demonstrated good anti-P. carinii pueumonia activity in a rat
model of the disease.
The incidence of Pneumocystis carinii pneumonia (PCP) has increased dramatically in the
United States with the advent of acquired immunodeficiency syndrome (AIDS). Over 70%
of AIDS patients develop PCP1. This opportunistic infection is the common cause of
mortality of AIDS patients. The first line of therapy of PCP is either trimethoprim-
sulfamethoxazole or pentamidine isethionate. These drugs precipitate serious adverse
effects2,3 hence there is the need for new less toxic agents for treating PCP (eg. atovaquone,
a hydroxy-1,4-naphthoquinone with limited side effects has recently been approved for
treatment of mild to moderate PCP in AIDS patients).
At the molecular level pentamidine is known to interact with a number of macromolecules
however the exact mechanism by which the drug achieves its anti-PCP activity is yet to be
established.4–8 This set-back coupled with the fact that the metabolic activity of P. carinii is
poorly understood have limited anti-P. carinii drug discovery to an empirical approach.9
Structure-activity relationship studies demonstrated that ether bridge contracted homologues
of pentamidine (1), such as butamidine (2), and propamidine (3) are as active as pentamidine
in treating experimental PCP in a rat model of the disease.10
Pentamidine and its analogues such as butamidine are flexible molecules hence they can
assume a variety of interconvertible conformations. The significance of reducing
conformational flexibility of these compounds on biological activity is unknown. We have
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synthesized compounds 4–7 as conformationally restricted congeners of pentamidine. These
compounds demonstrated good anti-PCP activity with no toxic side effects in a rat model of
the disease (table 1).
The following scoring criteria were used to evaluate the compounds for toxicity in vivo: A
score of 0 was assigned if no local, clinical, or histologic toxicity was observed; 1+, if all
aminals survived with no observable distress, but some local toxicity; 2+, if most animals
survived with severe distress and marked local toxicity as well as some clinical toxicity and
histopathology; 3+, if an acute toxic effect occurred after a single dose and/or a sharp
decrease in animals' health following multiple doses and resulted in loss of less than 50% of
the animals; 4+, if more than 50% of the animals died at the test dose.
Synthesis of 411 commenced with a Williamson ether synthesis between 4-cyanophenol and
cis -1,4-dichloro-2-butene to give dicyano 10. Subjection of 10 to Pinner reaction12 followed
by refluxing the resulting imidate 11 in methanolic ammonia gave bisamidino derivative 4.
Treatment of imidate 11 with a five fold excess of ethylenediamine in absolute methanol at
reflux gave bisimidazolino derivative 6. Trans isomers 5 and 7 were synthesized following
the above procedures but using trans -1,4-dichloro-2-butene in place of the cis isomer.
Compounds 4–7 were evaluated for anti-PCP activity as well as toxicity in a rat model of the
disease following standard procedures.10,13,14 Pentamidine was used as positive control and
saline as negative control. Table 1 shows the results of these studies. Efficacy of each
compound is presented as number of cysts counted per gram of lung tissue expressed as a
percentage of the number of cysts counted per gram of lung tissue for the saline treated
animals. The number of cysts per gram of lung tissue in all treatment groups were
significantly lower than that of the saline treated control. Pentamidine and its semi-rigid
analogues 4–7 were effective in treating P. carinii infection in the rat model. All the test
compounds were more potent than pentamidine as anti-PCP agents. Trans bisamidino
derivative 5 was the most potent compound studied being over five times more effective
than pentamidine. The test compounds precipitated no toxic side effects compared to the
pentamidine which caused severe distress, marked local toxicity, some clinical toxicity and
histopathology. No significant difference in anti-PCP activity or toxicity was observed
between the cis and trans isomers especially for the bisimidazolino derivatives 6 and 7.
This study supports our eailier finding that ether bridge contracted homologues of
pentamidine are effective anti-PCP agents.10 The study however did not demonstrate any
significant difference between the geometric isomers in terms of anti-PCP efficacy or
toxicity. Rigid analogues rather than semi-rigid derivatives are currently being developed in
our laboratory for conformation biological activity relationship studies of diamidines and
diimidazolines as anti-PCP agents.
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